


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.98%
+0.18%
+0.37%
+4.21%
KRRO
Korro Bio Inc.
$5.86
Strengths

Earnings are forecast to grow
Chart
$40.08 (-85.38%)
$23.08 (-74.61%)
$21.58 (-72.85%)
$21.58 (-72.85%)
KRRO has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Hit 52-week low

High volatilty

KRRO overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
KRRO Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
KRRO Street Sentiment is unimpressive but have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is KRRO current stock price?
What are KRRO stock strengths?
What is KRRO Risk Level?
What is KRRO market cap and volume?
What is KRRO current Stock IQ?
Should I buy KRRO stock right now?
Is KRRO a Strong Buy right now?
What does a 'Strong Buy' rating mean for KRRO?
What does a 'Strong Sell' rating mean for KRRO?
What factors influence KRRO's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.98%
+0.18%
+0.37%
+4.21%
KRRO
Korro Bio Inc.
Current Price
$5.86
Stock Insights
Strengths

Earnings are forecast to grow

Chart
$40.08 (-85.38%)
$23.08 (-74.61%)
$21.58 (-72.85%)
$21.58 (-72.85%)
KRRO Analysts Opinion
KRRO Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
KRRO Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
KRRO Street Sentiment is unimpressive but have positive views on the near-term outlook
KRRO has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Hit 52-week low

High volatilty

Average key support and resistance price levels.
KRRO Latest Analysis
Jefferies Maintains Buy Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning. With significant upside potential Wave Life Sciences Ltd. (NASDAQ:WVE) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 13 2025 Jefferies analyst Roger Song noted that Wave Life Sciences Ltd. (NASDAQ:WVE)s competitive positioning is improving with Korro Bios KRRO-110 reporting failure to produce protective levels [….]
Mon Nov 17, 2025
Korro Bio Early Trial Results Fall Short. Stock Hits New Low. ) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million as per data from .The genetic medicines company provided a program update for its Phase 1/2a REWRITE clinical trial of KRRO-110 in .AAT deficiency is a genetic disorder where the body doesn'.t produce enough of the AAT protein which protects the lungs and liver from damage.Also Read: The company announced that KRRO-1
Thu Nov 13, 2025
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial.
Thu Nov 13, 2025
Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing. Korro Bio stock plummeted Thursday after its RNA-editing drug failed to pass muster in patients with a rare lung and liver disease.The post Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing appeared first on Investor'.s Business Daily.
Thu Nov 13, 2025
Korro To Slash 34% Workforce. Stock Plunges . (RTTNews) - Korro Bio Inc. (KRRO) a clinical-stage biopharmaceutical company pioneering RNA editing therapies today announced its third quarter 2025 financial results and provided a comprehensive update on its advancing pipeline.
Thu Nov 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
KRRO Stock trends
KRRO Stock performance
KRRO Stock analysis
KRRO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.